Drug Database
ES

esomeprazole

✓ Approved

Nanodaru · ATP4A · 小分子

什么是 esomeprazole?

esomeprazole 是一种小分子,由Nanodaru研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

公司Nanodaru
药物类别小分子
分子靶点ATP4A
给药途径Injectable (Others), Intravenous (IV)
状态Approved

作用机制

分子靶点

esomeprazole 作用于 1 个分子靶点:

ATP4AATPase H+/K+ transporting subunit alpha (ATP6A)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

esomeprazole 针对 3 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Gastrointestinal disordersDuodenal ulcer✓ Approved
Gastrointestinal disordersGastric ulcer✓ Approved
Gastrointestinal disordersGastrooesophageal reflux disease✓ Approved

相关研究文献

PubMedThe Journal of pharmacy and pharmacology2026-11-17

Esomeprazole upregulates Nrf2/HO-1 pathway and attenuates profibrotic response in dermal fibroblasts derived from patients with systemic sclerosis.

Koniyan Shaheer S, Khan Mohammad A MA, Ahir Manisha M, Jegga Anil G AG et al.

To investigate whether esomeprazole attenuates profibrotic responses in dermal fibroblasts from patients with systemic sclerosis (SSc), as well as inflammatory and oxidative stress-related responses in dermal endothelial cells, and to evaluate its effects on nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) signaling pathway. To evaluate this, primary dermal fibroblasts from patients with limited SSc were stimulated with transforming growth factor-beta 1 (TGF-β1) to induce profibrotic processes and then treated with esomeprazole. Functional studies showed that esomeprazole reversed aberrant fibroblast contractility, and RNA sequencing (RNA-seq) analysis demonstrated that esomeprazole upregulated antioxidant gene networks and downregulated profibrotic pathways. Intriguingly, the upregulation of HO-1 by esomeprazole was blunted upon genetic deletion of the Nrf2 gene. Microvascular injury is an early event in scleroderma and a precursor of fibrosis. As such, we treated microvascular endothelial cells with the prooxidant molecule bleomycin, with and without esomeprazole, and found that esomeprazole attenuated the expression of pro-inflammatory cytokines. Together, these results suggest that esomeprazole upregulates the Nrf2/HO-1 pathway and attenuates profibrotic responses in SSc dermal fibroblasts and reduces inflammatory and oxidative stress-related responses in dermal endothelial cells, supporting further evaluation of the drug in preclinical scleroderma models.

PMID 43043866
阅读全文 →
PubMedInternational urology and nephrology2026-11-15

Comparative analysis of kidney adverse events associated with four commonly used proton pump inhibitors based on the PersADE database.

Guo Xianyang X, Chen Peizhen P, Chen Rujie R, Jin Shengwei S

Proton pump inhibitors (PPIs) are widely prescribed, yet their association with kidney injury has drawn increasing concern. Using the PersADE database, we compared kidney adverse drug event (ADE) signals for four oral PPIs (omeprazole, esomeprazole, lansoprazole, pantoprazole) and described reporting patterns by age, body weight, and sex for omeprazole and esomeprazole. In this retrospective pharmacovigilance disproportionality analysis, we retrieved spontaneous reports of nine predefined MedDRA kidney ADE categories with PPIs as the primary suspected drug. Signal detection employed reporting odds ratio (ROR) and proportional reporting ratio (PRR), with positive signals defined as case count ≥ 3, ROR ≥ 2, PRR ≥ 2, and χ2 ≥ 4. Subgroup analyses were descriptive and hypothesis-generating; no formal statistical testing or adjustment for confounders was performed. Due to high missing rates for demographic variables, subgroup analyses were limited to omeprazole and esomeprazole. All four oral PPIs generated positive kidney ADE signals across multiple categories. However, pantoprazole showed no detectable signals for Acute tubular necrosis, chronic kidney disease-mineral and bone disorder or renal cancer. Higher reporting counts were observed in patients aged ≥ 70 years and those weighing > 80 kg, whereas sex was not associated with appreciable differences in reporting counts. All four PPIs exhibit clear kidney ADE signals. The subgroup findings are descriptive and hypothesis-generating rather than established risk factors. These findings suggest that clinicians may consider caution and renal function monitoring in elderly or overweight patients, although further validation is needed.

PMID 43034236
阅读全文 →
PubMedJournal of separation science2026-11-15

Rapid Determination of Esomeprazole by Chiral Capillary Electrophoresis Using Dual-Programmed Voltage and Pressure.

Yun Jihyun J, Jung Hyunjin H, Sohn Seil S, Kang Seong Ho SH

Accurate quantification of (S)-omeprazole is essential to ensure the quality, efficacy, and safety of pharmaceutical formulations. In this study, a chiral capillary electrophoresis (CE) method using dual-programmed voltage and pressure was developed for the rapid determination of (S)-omeprazole, overcoming the inherent trade-off between speed and separation efficiency in conventional CE methods. Under the optimized dual-programmed, stepped chiral CE condition (28 kV + 0.69 kPa, 0-6 min → 25 kV, 6-11 min → 20 kV, 11-14 min → 28 kV + 1.38 kPa, 14-20 min), (S)- and (R)-omeprazole were separated within 12.4 min with a resolution of 2.21. The method showed good linearity over an (S)-omeprazole concentration range of 25-250 µM (correlation coefficient, R = 0.9969), with a limit of detection of 25 µM. The method was successfully applied to a commercial tablet formulation, and a t-test revealed no statistically significant difference between it and prepared standard solutions at the 95% confidence level. Compared with conventional high-performance liquid chromatography methods designed for assay and organic impurity testing, the proposed CE method enables rapid routine chiral assay of (S)-omeprazole while maintaining baseline enantioseparation. These results demonstrate the suitability of the chiral CE method for the routine chiral assay of (S)-omeprazole in pharmaceutical formulations.

PMID 43032896
阅读全文 →
PubMedJournal of clinical medicine2026-11-14

Late Delayed Bleeding After Gastric ESD with Esomeprazole/Sodium Bicarbonate Versus Conventional Esomeprazole, and Artificial Ulcer Healing with Esomeprazole/Sodium Bicarbonate: A Retrospective Cohort Study.

Nam Hyeong-Seok HS, Ryu Dae-Gon DG, Kim Su-Jin SJ, Park Su-Bum SB et al.

Background/Objectives: Artificial ulcers after gastric endoscopic submucosal dissection (ESD) generally heal within 8 weeks with proton pump inhibitor (PPI) therapy; however, delayed bleeding remains a clinically relevant complication. Esomeprazole/sodium bicarbonate is an immediate-release PPI formulation; its role after ESD is unclear. Methods: This single-center retrospective study included 923 patients who underwent gastric ESD from July 2017 through December 2025. Late delayed bleeding, defined as bleeding after second-look endoscopy, was compared between patients receiving esomeprazole/sodium bicarbonate (n = 532) and conventional esomeprazole (n = 391) using Firth logistic regression adjusted for calendar period and clinical factors. Eight-week artificial ulcer healing was assessed descriptively only in the esomeprazole/sodium bicarbonate group (n = 527). Results: Late delayed bleeding occurred in 26/923 patients (2.8%): 16/532 (3.0%) in the esomeprazole/sodium bicarbonate group and 10/391 (2.6%) in the conventional esomeprazole group. PPI formulation was not associated with late delayed bleeding (adjusted OR 0.872; 95% CI 0.313-2.427). Submucosal fibrosis (adjusted OR 4.502; 95% CI 1.969-10.292), antiplatelet use (adjusted OR 3.620; 95% CI 1.617-8.103), and anticoagulant use (adjusted OR 6.783; 95% CI 1.323-34.770) were independently associated with bleeding. All 26 patients with bleeding were men; sex was therefore excluded from the model. Complete healing was observed in 510/527 patients (96.8%); ulcer diameter ≥ 40 mm was independently associated with incomplete healing (adjusted OR 7.114; 95% CI 2.664-18.998). Conclusions: No statistically significant difference in late delayed bleeding was detected between formulations, although a clinically meaningful difference cannot be excluded. Healing was assessed only in the esomeprazole/sodium bicarbonate group and could not be compared between formulations. Late delayed bleeding was associated with submucosal fibrosis and antithrombotic therapy.

PMID 43030598
阅读全文 →
PubMedPolymers2026-11-14

Polymer Selection for Esomeprazole Solid Dispersions: Drug-Polymer Compatibility Assessed by Forced Degradation, ATR-FTIR, and DFT Calculations.

Ahumada-Herazo Edgar E, Urrego A Juan R JR, Baena-Aristizábal Claudia C, Carrascal Juan José JJ et al.

Esomeprazole (ESO) is susceptible to degradation under stress conditions, making polymer selection important for stable solid dispersions. This study evaluated ESO compatibility with five polymers: three grades of hydroxypropyl methylcellulose acetate succinate (HPMCAS-LMP, HPMCAS-MMP, and HPMCAS-HMP), hydroxypropyl methylcellulose phthalate (HPMCP-55), and methacrylic acid-ethyl acrylate copolymer (1:1; Eudragit® L100-55). Esomeprazole, polymers, and binary mixtures were stored at room temperature and subjected to forced thermal degradation at 60 °C for 16 days. Spectral changes were assessed by visual inspection and attenuated total reflectance-Fourier transform infrared (ATR-FTIR) spectroscopy using the fractional change index (FCI), normalized root-mean-square deviation (NRMSD), and relative maximum spectral difference (relative Max Δ). Density functional theory (DFT) calculations examined interaction energies, non-covalent interactions (NCIs), frontier molecular orbitals, and HOMO-LUMO-based reactivity descriptors. Combining quantitative ATR-FTIR analysis under thermal stress with DFT provides complementary experimental and molecular-level insights into ESO-polymer interactions, including an experimental comparison of three HPMCAS grades. The ESO-HPMCAS-MMP mixture showed the smallest spectral deviations. DFT indicated favorable interactions and relatively low chemical reactivity for the modeled ESO-HPMCAS complex. These findings support the preliminary consideration of HPMCAS-MMP for further formulation studies, although additional evidence is needed to establish comparative chemical compatibility and stability.

PMID 43029943
阅读全文 →
PubMedBiology2026-11-14

Beyond Acid Suppression: Mechanistic and Translational Perspectives on the Pleiotropic Pharmacology of Pantoprazole.

Satyam Shakta Mani SM, Kumar Manasvi Udaya MU, Safaii Ebrahim E, Al-Dawoodi Shams S et al.

Pantoprazole is widely used for the management of acid-related gastrointestinal disorders through inhibition of the gastric H+/K+-ATPase. Beyond its established acid-suppressive action, experimental studies have investigated its potential effects on cellular proton homeostasis, autophagy, oxidative and inflammatory signaling, cancer biology, antimicrobial resistance, glucose regulation, neurological responses, hepatic fibrosis, and iron-related outcomes. This narrative review critically examines these proposed biological effects and distinguishes established pharmacology from experimental mechanisms, preclinical findings, and human clinical evidence. Particular attention is given to the relationship between experimental concentrations and human exposure, the acid-dependent activation of pantoprazole, the distinction between direct molecular targets and downstream cellular responses, and the challenges of translating laboratory findings into clinical benefit. Pantoprazole also has a comparatively favorable CYP2C19-mediated drug-interaction profile relative to omeprazole and esomeprazole, although this advantage does not imply the absence of all clinically relevant interactions. The evidence across proposed repurposing indications remains heterogeneous, and biological activity in experimental models should not be interpreted as established therapeutic efficacy. Further exposure-informed mechanistic studies, pharmacokinetic and pharmacodynamic validation, and appropriately designed clinical trials are required to determine which proposed effects warrant clinical development. Pantoprazole should therefore be regarded as a candidate for mechanism-informed drug-repurposing research rather than an established treatment for the non-gastrointestinal indications discussed in this review.

PMID 43026948
阅读全文 →

注册免费账户还可查看另外 2286 篇文献

免费注册查看全部文献 →

了解更多esomeprazole